Literature DB >> 16801668

Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.

R B Postuma1, A J Espay, C Zadikoff, O Suchowersky, W R W Martin, A-L Lafontaine, R Ranawaya, R Camicioli, A E Lang.   

Abstract

Elevated homocysteine is associated with increased risk of heart disease, stroke, and dementia. Therapy of Parkinson disease (PD) with levodopa elevates homocysteine. The authors conducted a 6-week, multicenter, randomized, double-blind, placebo-controlled trial to test whether folate 1 mg/vitamin B(12) 500 microg or entacapone reduced serum homocysteine in 35 levodopa-treated PD patients. Levodopa initiation caused a small elevation in homocysteine. Vitamin therapy, but not entacapone, resulted in a decrease in homocysteine compared to placebo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16801668     DOI: 10.1212/01.wnl.0000219815.83681.f7

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients.

Authors:  D Caccamo; G Gorgone; M Currò; G Parisi; W Di Iorio; C Menichetti; V Belcastro; L Parnetti; A Rossi; F Pisani; R Ientile; P Calabresi
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

2.  Possible treatment concepts for the levodopa-related hyperhomocysteinemia.

Authors:  Thomas Müller
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-09-09

Review 3.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

4.  Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.

Authors:  Thomas Müller; Dirk Woitalla; Siegfried Muhlack
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-02       Impact factor: 3.000

5.  Cobalamin deficiency, hyperhomocysteinemia, and dementia.

Authors:  Steven F Werder
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

6.  Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo).

Authors:  Paolo Solla; Antonino Cannas; Francesco Marrosu; Maria Giovanna Marrosu
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

7.  Peripheral COMT inhibition prevents levodopa associated homocysteine increase.

Authors:  Thomas Müller; Siegfried Muhlack
Journal:  J Neural Transm (Vienna)       Date:  2009-08-06       Impact factor: 3.575

Review 8.  Potential influences of complementary therapy on motor and non-motor complications in Parkinson's disease.

Authors:  Theresa A Zesiewicz; Marian L Evatt
Journal:  CNS Drugs       Date:  2009-10       Impact factor: 5.749

9.  Nutritional therapies in Parkinson's disease.

Authors:  Marian L Evatt
Journal:  Curr Treat Options Neurol       Date:  2007-05       Impact factor: 3.598

10.  Hyperhomocysteinemia in patients with Parkinson's disease and relationship to vitamin B level.

Authors:  Hae-Won Shin; Young Ho Sohn
Journal:  J Mov Disord       Date:  2009-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.